# Organic & **Biomolecular Chemistry**

Accepted Manuscript



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

*Accepted Manuscripts* are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this *Accepted Manuscript* with the edited and formatted *Advance Article* as soon as it is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](http://www.rsc.org/Publishing/Journals/guidelines/AuthorGuidelines/JournalPolicy/accepted_manuscripts.asp).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](http://www.rsc.org/help/termsconditions.asp) and the Ethical quidelines still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.



www.rsc.org/obc

## **Design, synthesis and evaluation of new tricyclic endoperoxides as potential antiplasmodial agents**

Jérémy Ruiz,<sup>a</sup> Sonia Mallet-Ladeira, <sup>b</sup>Marjorie Maynadier, <sup>c</sup> Henri Vial, <sup>c</sup> Christiane André-Barrès<sup>a\*</sup>

a Laboratoire de Synthèse et de Physicochimie de Molécules d'Intérêt Biologique, UMR CNRS 5068, Université Paul-Sabatier, 118 route de Narbonne, F-31062 Toulouse cedex 4, France.

<sup>b</sup>Institut de Chimie de Toulouse, FR2599, Université Paul-Sabatier, 118 route de Narbonne, F-31062 Toulouse cedex 9, France.

c Dynamique des Interactions Membranaires Normales et Pathologiques, UMR CNRS 5235, Université Montpellier 2, Place E. Bataillon, F-34095 Montpellier cedex 5, France.

Corresponding author E-mail: candre@chimie.ups-tlse.fr

**Key Words**: malaria, endoperoxide, C-centered radical, hybrid molecule, *Plasmodium falciparum*, G-factor.

### **Abstract**

Diastereoselective autoxidation allowed preparation of new tricyclic endoperoxides. These compounds and their methylated analogs were evaluated against the *in vitro* growth of *Plasmodium falciparum,* the malaria-causing parasite, showing moderate activities. However, hybrid molecules constituted of the tricyclic peroxide moiety and 7-chloro-4-aminoquinoline were synthesized and displayed a marked increase in antiplasmodial activity.

### **Introduction**

The emergence of artemisinin-resistant *Plasmodium falciparum* in Southeast Asia has exacerbated the need and stimulated search of new synthetic molecules that possess antimalarial activity. Consequently, we continue our efforts to design and synthesize new Gfactor analog endoperoxides. The new compounds will act as artemisinin or artemisinin-like compounds. They will have to form after Fe(II) induced reduction, C-centered radicals potentially able to alkylate heme or to react with vital biomolecules.<sup>1</sup> Primary or/and secondary C-centered radicals have been described after Fe(II) induced reduction of artemisinin or its derivatives,<sup>2</sup> trioxanes,<sup>3</sup> trioxolanes,<sup>4</sup> tetraoxanes<sup>5</sup> or arteflene.<sup>6</sup> (Scheme 1)



**Scheme 1**: Fe(II)-induced primary or secondary C-centered radical formation

Previous studies have shown that endoperoxides belonging to the G-factor family, natural compounds extracted from leaves *of Eucalyptus grandis*, 7 possess interesting antimalarial properties after methylation of the hydroxyl group of the peroxyhemiketal moiety. The concentration of the methylated endoperoxide to inhibit by 50% the growth of chloroquine sensitive and resistant *P. falciparum* strains (IC50) was in the range of 200-300 nM i.e. was 100-fold better than the hydroxylated one, the fluorinated being inactive.  $8.9\text{ A}$  study of the Fe(II)-induced reduction of these three compounds<sup>10</sup> has shown the presence of a tertiary Ccentered radical which cyclizes in 5-*exo*-trig manner in all cases. Only in the case of the G3Me, competition between 5-*exo*-trig cyclisation and disproportionation of the radical does occur, favoring disproportionation which becomes the prevalent mechanism (disproportionation / cyclization: 70/30). So this tertiary C-centered radical can indeed interact with vital biomolecules of the parasite, for instance alkylating the heme, explaining the effect observed on antimalarial activity. In contrast, in the case of G3 or G3F, the radical is more reactive and lead to self-quenching *via* cyclization in a 5-*exo*-trig manner finally giving rise to Fe(II) and a neutral molecule.

So, in order to obtain secondary radicals as described for known antimalarial peroxides acting like artemisinin, we designed tricyclic endoperoxide analogs of known G-factor derivatives. Fe(II)-induced reduction could indeed afford secondary C-centered radicals. In this case, the 5-*exo*-trig cyclisation could be preferentially replaced by an intermolecular addition on heme or parasite vital biomolecules. (Scheme 2)

### **Results and discussion**

 The aim of this work was to synthesize and evaluate antimalarial properties of these new tricyclic endoperoxides. Synthesis is based on an autoxidation step on dienol intermediates as previously described for the G-factors and analogs.<sup>11</sup> These precursors were obtained following a modified Knoevenagel-type procedure in two steps from bicyclic dienone.

Furthermore, a patent from Syngenta, described the synthesis of bicyclic diones used as precursors in herbicide synthesis.<sup>12</sup>



**Scheme** 2**:** Hypothesis of Fe(II)-induced reduction

### **I. Synthesis of bicyclo[3.2.1]oct-6-ene-2,4-diones 6 and 7**

Synthesis of bicyclo[3.2.1]oct-6-ene-2,4-dione **6** was optimized following the patent description.<sup>12</sup>

The first step was a [4+2] cycloaddition reaction between cyclopentadiene and perchloropropene **2** previously obtained *in situ* after HCl elimination from pentachlorocyclopropane **1**. The Diels-Alder adduct **3** rearranged itself into tetrachlorinated product **4**. 13 Product **5** was then obtained after chloride substitution by hydroxide, using sodium hydroxide in water/dioxane mixture. The C-Cl bond of product **5** was reduced by Zn(0) in acetic acid/dioxane 4/6 to afford dione **6** in 30% yield in a three-step reaction (Scheme 3).



**Scheme 3**: Synthesis of diones **6**, **7**: a) KOH, dioxane, RT, 1h then cyclopentadiene, 85°C, 2h, 81% b) NaOH/H2O, 90°C, 18h, 59% c) Zn, 3 eq, RT, dioxane/AcOH 6/4, 20 h, 62% d) Pd/C H2 dioxane/EtOAc, 1h e) Pd/C, H2, 55°C dioxane/EtOAc

The patent also describes the bicyclo[3.2.1]octane-2,4-dione **7** in 59% yield, by hydrogenation and reduction of product **5** in the presence of acetic acid and a catalytic amount of Pd/C (0.1 eq.) at  $55^{\circ}$ C in dioxane under 1 bar H<sub>2</sub>.

Following these conditions product **8** was obtained in 58% yield after 6 hours of hydrogenation. If the reaction is left longer (17 hours) the alcohol **9** was isolated in lower yield (34%). Finally the dione **7** was obtained in good yield from the unsaturated dione **6** after one hour of catalytic hydrogenation at room temperature in the mixture dioxane/ethyl acetate.

### **II. Syntheses of tricyclic peroxides**

Tricyclic peroxides were synthesized following a previously described procedure<sup>11</sup> with autoxidation as a key step. Mannich bases were prepared by reaction of the bicyclooctanediones **6** or **7** with the iminium obtained from isobutyraldehyde and piperidine. After treatment with saturated NH4Cl in HCl (1M), precursors **10** and **13** were obtained in 89% and 98% yields respectively (Scheme 4).

Autoxidation reactions on precursors **10** and **13** were then optimized by varying different conditions: solvent (ethyl acetate or benzene),  $O_2$  pressure (air, 1 and 5 bars), UV irradiation (300 nm or 350 nm).

Precursor 10 is in equilibrium between its dienone form 10a and dienol 10b as shown the <sup>1</sup>H NMR spectroscopy analysis of the precursor **10**.



**Scheme 4:** Synthesis of endoperoxides **11** and **14**

Autoxidation under  $O_2$  (1 bar) in ethyl acetate was quite slow and led to the formation of endoperoxide **11** in 60% yield along with epoxide **12** in 7% yield after 4 days. The reaction was accelerated in benzene as endoperoxide was observed alone in around 50% yield after one day under  $O_2$  pression of 1 bar or after only 4 hours under  $O_2$  pression of 5 bars.

Photoenolization of **10** using a Rayonet apparatus equipped with 350 nm low pressure mercury lamps, under  $O_2$  (1 bar) in deuterated benzene allowed the formation of dienol 10b, in a  $1/1$  mixture with enone **10a** after 15 minutes of irradiation as indicated by <sup>1</sup>H NMR spectroscopy. After 3 hours, the peroxide **11** was then obtained with 48% yield.

Concerning precursor  $13$ , <sup>1</sup>H NMR did not indicate the presence of the dienol form  $13b$ . As autoxidation proceeds on this form, oxygen uptake proved to be very slow in this case as it

took several days (50% after 30 days in ethyl acetate).  $O_2$  pressure did not accelerate the overall kinetics.

As previously described, photoenolization was then attempted using ethyl acetate or benzene as solvent. At 350 nm dienol **13b** in mixture with the enone form **13a** along with its deconjugated form, was detected by  ${}^{1}H$  NMR. Then autoxidation occurred quickly in competition with displacement of the equilibrium towards the enone form. So, several cycles consisting of irradiation for 15 mn followed by autoxidation under  $O_2$  (1 bar) for 45 mn, allowed endoperoxide formation with roughly 45% yield after 8 cycles. Whatever the solvent, yield and reaction time were similar. In this case, enolization seems to be the rate-limiting step of the global kinetics.

Both endoperoxides **11** and **14** were obtained as single diastereoisomers. Both compounds could be crystallized and crystals were analyzed by X-ray diffraction.<sup>14</sup>

Endoperoxide 11 crystallizes in a triclinic structure ( $a = 6.47 \text{ Å}$  b = 8.74 Å, c = 10.93 Å,  $\alpha$  = 110.2°,  $\beta$  = 95.6°,  $\gamma$  = 101.3°).<sup>15</sup> Using numbering indicated in figure 1 and used in X-ray diffraction analysis, its configuration is 1S,4R,5R or 1R,4S,5S.

Endoperoxide 14 crystallizes in a monoclinic structure (( $a = 6.50 \text{ Å}$ ,  $b = 20.28 \text{ Å}$ ,  $c = 8.37 \text{ Å}$ ,  $\alpha = 90^{\circ}$ ,  $\beta = 99.7^{\circ}$ ,  $\gamma = 90^{\circ}$ ).<sup>16</sup> Its configuration is also 1S,4R,5R or 1R,4S,5S.

The hydroxyl and the methylene C8 groups are on the same side for both endoperoxides so the diastereoisomers are called **11** *cis* and **14** *cis* respectively.

To compare the energy level of the two diastereoisomers **11***cis* and **11***trans* on the one hand, and **14***cis* and **14***trans* on the other hand, the four structures were fully optimized using density functional theory (DFT) and the GAUSSIAN 09 software package.<sup>17</sup> We chose the B3LYP hybrid functional.<sup>18</sup> The computations were done with the B3LYP/6-311+G(d,p) scheme and the stationary points were characterized as minima by a vibrational analysis. Geometries and enthalpies of the four compounds are presented in figure 2. The gaps between the two enthalpy levels of **11***cis* and **11***trans* on the one hand and **14***cis* and **14***trans* on the other hand, are  $0.8$  kcal.mol<sup>-1</sup> and  $0.3$  kcal mol<sup>-1</sup> respectively. Those values are too low to explain the selectivity observed. Probably a higher transition state must be reached in both cases during the reaction path leading to **11***trans* **(14***trans***)** than **11***cis* **(14***cis***)**.

Geometries of both diastereoisomers were compared with the geometry of endoperoxides 6-**Endo** and **7-Endo** (Figure 2) obtained after autoxidation of 2-alkylidene cyclohexane dione and 2-alkylidene cycloheptane dione. The geometry obtained for **11***cis* (14*cis*) is similar to that of 6-Endo with a chair conformation for the 6-membered cycle while for 11*trans* (14*trans*), the 6-membered cycle adopts a boat conformation. We have previously shown that kinetics of autoxidation is considerably lower in the case of 2-alkylidene cycloheptane dione. So it seems that both  $11 cis$  and  $14 cis$  obtained are the kinetic products.<sup>19</sup>



**Figure 1**: ORTEP molecular view of endoperoxides 11 and 14 in the solid state (thermal ellipsoids at 50% probability; hydrogen atoms are omitted for clarity).





Figure 2: Optimized geometries and enthalpies of 6-Endo, 7-Endo, 11*cis* and 11*trans*, 14*cis* and  $14$ *trans* at the B3LYP 6-311+G(d,p) level of theory

Previous works have shown the crucial role of the methylation of the peroxyhemiketal position<sup>9, 11</sup> so, methylation of 11 and 14 was planned.

First attempts with  $K_2CO_3$ , Li<sub>2</sub>CO<sub>3</sub> in DMF, using MeI or  $(MeO)_2SO_2$  as methylating agent at room temperature did not work, only starting material was totally recovered. When  $Cs_2CO_3$ was used as base, whatever the methylating agent used (MeI or  $(MeO)_2SO_2$ ), degradation occurred. Finally, butyl lithium (1 eq.) at -78°C, in THF, followed by addition of TfOMe afforded endoperoxides 15 and 16 in about 50% yield, 50% of the starting material was recovered. Increasing equivalent of BuLi (2 eq) due the presence of another acidic proton in the  $\alpha$ -position of the carbonyl, did not increase the yield of methylated endoperoxides and starting material recovery decreased too.



**Scheme 5 :** Methylation of endoperoxides **11** and **14** 

### **III. Hybrid molecules**

Our recent work concerning the synthesis of hybrid molecules containing an endoperoxide moiety belonging to the G-factor family linked to a second pharmacophore, e.g. a streptocyanine or a 7-chloro-4-aminoquinoline, has shown this approach can increase antiplasmodial activity.<sup>20</sup> So we decided to prepare hybrid molecules with a dual mode of action containing the tricyclic endoperoxide and a 7-chloro-4-aminoquinoline mimicking chloroquine. We designed and synthesized a functionalized aldehyde which could easily lead to enone precursor of autoxidation. A piperidine linker was chosen to avoid the formation of diastereoisomers after autoxidation.

Starting from 4,7-dichloroquinoline, alcohol **17** was first obtained after substitution of the chloride by 4-piperidinyl-methanol. Oxidation of **17** by 2-iodoxybenzoic acid (IBX) in refluxing acetone led to aldehyde **18** quantitatively.



**Scheme 6:** Preparation of aldehyde **18** 

Then this aldehyde **18** was added to diones **6** and **7** following the previous Knoevenagel modified procedure: formation of the iminium by condensation of one equivalent of piperidine on the aldehyde, addition of this iminium to diones **6** and **7** furnishing the Mannich bases, then aqueous acidic treatment allowing the formation of precursors **19** and **20** in 99% and 67% yields respectively in the three-step reaction.

<sup>1</sup>H NMR spectra of these precursors indicated in both cases that they were present only in the enone form. As previously, autoxidation occurred very slowly on both structures and endoperoxides **21** and **22** were obtained in respectively 19% and 34% yield, after 33 and 15 days in ethyl acetate under  $O_2$  (1bar). An increase of the  $O_2$  pressure to 10 bars did not enhance the rate of oxygen uptake. So, photoenolization was attempted at 350 nm, 300 nm and 254 nm but no dienol form appeared as shown by  ${}^{1}H$  NMR spectroscopy. Incidentally we realize that deposing precursor **20** on silica gel allowed its enolization. The dienol was then trapped by  $O_2$  helping to shift the equilibrium in favor of the dienol, so allowing formation of endoperoxide **22** with a great increase of the global rate: 3 hours over 2 weeks. The same procedure was tried for precursor **19** without success, the starting material being entirely recovered in the enone form. As previously, a single diastereoisomer was obtained in both cases. NMR spectroscopy analysis allowed concluding that the hydroxyl and the methylene are on the same side as their 1 H NMR spectra present the same pattern as for **11** and **14**.



**Scheme 7:** Synthesis of hybrid endoperoxides **+/**- **21** and **+/**- **22** 

Methylation in this series was particularly risky and delicate as several positions could be methylated. After several trials, and several conditions, only endoperoxide **21** was methylated using BuLi/TfOMe (1 eq/1 eq) at low temperature in THF, affording **23** in a low yield after purification by silica gel chromatography (16%).



**Scheme 8:** Methylation of endoperoxide **21**: BuLi/THF, -78 °C, then TfOMe, 16%

### **IV. Antimalarial activity**

Endoperoxides **11, 14**, **21** and **22** and their methylated analogs **15**, **16** and **23** were tested *in vitro* against the chloroquine-sensitive 3D7 strain and the chloroquine-resistant W2 strain of *Plasmodium falciparum* (Table 1). The activities were determined according to Desjardins et al. using  $[3H]$  hypoxanthine incorporation to assess parasite growth. Parasitic viability was expressed as  $IC_{50}$ , the drug concentration causing 50% parasite growth inhibition.<sup>21</sup>

In contrast to previous results,  $9, 11$  methylation of 11 and 14 allowed only a slight increase in activity (respectively 4-fold and 2-fold for the methylated endoperoxides **15** and **16**). However, as previously, methylation of **21** provided endoperoxide **23** which was 28-32 fold more potent. The introduction of 7-chloro-4-aminoquinoline improved the activity. Indeed the hybrid endoperoxide  $23$  was 16-fold to 25-fold more potent than 16, with an IC<sub>50</sub> below 1 µM, both on 3D7 and W2 parasite strains.

**Table 1:** IC<sub>50</sub> values of several endoperoxides, artemisinin (ART) and chloroquine on chloroquinesusceptible (3D7) and chloroquine–resistant (W2) strains of *Plasmodium falciparum* 

	11	14	15				16 21 22 23 G3 G3Me ART Chloroquine
$\frac{IC_{50}(\mu M)}{3D7}$ 31.5 10.55 7.75 3.85 6.75 2.45 <b>0.24</b> 62 0.40 0.019							0.019
IC <sub>50</sub> (µM) (W2)						8.45  6.35  4.55  6.05  1.40  0.185  38  0.23  0.019	0.42

# **Drganic & Biomolecular Chemistry Accepted Manuscript Organic & Biomolecular Chemistry Accepted Manuscript**

### **Conclusion**

Endoperoxides were prepared following an autoxidation step in moderate to good yields. Oxygen uptake proved to be diastereoselective leading to peroxides **11** and **14**, with the same configuration (+/-)-*cis*. Unfortunately, those compounds presented very low activity whether methylated or not. The same methodology was followed for the preparation of hybrid molecules **21** and **22** combining the 7-chloro-4-aminoquinoline to the tricyclic endoperoxide moiety. The same diastereoselectivity during the autoxidation step was observed. After methylation of the peroxyhemiketal function, the hybrid compound **23** displayed a marked increase in its antiplasmodial activity, with an  $IC_{50}$  between 100 to 250 nM against both the chloroquine-susceptible and/or -resistant strains of *Plasmodium falciparum*. It seems that 7 chloro-4-amino-quinoline moiety can interact with heme by  $\pi$ - $\pi$  interaction, leading to the localization of the compound near its target, the heme. The heme provides iron(II) for reduction of the peroxide; the production of C-centered radical in the vicinity of heme renders alkylation feasible.

### **Experimental part**

### 2,3,4,4-tetrachlorobicyclo[3.2.1]octa-2,6-diene (**4**)

KOH pellets (369 mg, 5.60 mmol, 4.00 eq.) were powdered in 20 mL of dry toluene. Pentachlorocyclopropane **1** (0.7 mL, 4.9 mmol, 1.0 eq.) was added at room temperature under inert atmosphere. The suspension was stirred at room temperature for 1h. Freshly distilled cyclopentadiene was added dropwise. The reaction was heated at 85 °C for 2 h. The mixture was filtered through celite. The filtrate was concentrated to give 965 mg of a yellowish crystal (81 %). mp = 91°C; Rf = 0.65 (petroleum ether); <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  2.23 (1H, *td*, CH-C*H*2-CH), 2,49 (1H, *d*, CH-C*H*2-CH), 3.17-3.20 (1H, *m,* CCl=CCl-C*H*), 3.76-3.79 (1H, *m*, CCl<sub>2</sub>-CH), 6.19 (1H, *dd*, CCl-CH-CH=CH), 6.67 (1H, *dd*, CH=CH-CH-CCl<sub>2</sub>); <sup>13</sup>C NMR (75.47 MHz, CDCl3) δ 42.2 (CH2, CH-*C*H2-CH), 49,1 (CH, CCl-*C*H-CH2), 58.4 (CH, CCl2- *C*H-CH<sub>2</sub>) 88.9 (C, *CCl<sub>2</sub>*), 127.7 (C, *CCl<sub>2</sub>*-*CCl*=CCl), 132,7 (CH, *CCl*-CH-*CH*=CH), 140.6 (C, CH-*C*Cl=CCl), 141.8 (CH, CCl2-CH-*C*H=CH)

3-chlorobicyclo[3.2.1]oct-6-ene-2,4-dione (**5a**) and its enol isomer **5b**

2,3,4,4-tetrachlorobicyclo[3.2.1]octa-2,6-diene (**4)** (72 mg, 0.3 mmol, 1.0 eq.) was dissolved in 2 ml of dioxane. Then 1.5 ml of NaOH solution (2M), (3.0 mmol, 30 eq.) was added. The reaction was stirred at 90°C for 18h. The reaction was extracted with 10 ml of EtOAc. The aqueous layer was adjusted to pH 1 with HCl (6M) aqueous solution and extracted with 3x10

mL of EtOAc. Combined organic layers were washed with 15 mL of brine, dried over MgSO4 and concentrated to give 30 mg of a crude brownish solid (59 % yield).

 $mp = 137^{\circ}C$ ; Rf = 0.1 (petroleum ether/AcOEt; 50/50); <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) (**5a** and **5b** mixture) δ 2.33-2.50 (2H, *m*, CH-C*H*2-CH), 2.59-2.76 (2H, *m*, CH-C*H*2-CH), 3.53 (2H, *t*, CO-C*H*), 3.71-3.73 (1H , *m*, CO-C*H*), 3.82 (1H, *dd*, CO-C*H*), 5.22 (1H, *d*, COH-CH-C*H*=CH), 5.55 (1H, *d*, COH-CH-C*H*=CH), 6.19 (1H, *d*, CO-CH-C*H*=CH), 6.41-6.42 (1H, *m*, CO-CH-C*H*=CH), 6.52 (1H, *s*, C*H*Cl); <sup>1</sup> H NMR (300 MHz, MeOD) (**5b** major product) δ 2.38-2.44 (1H, *m,* AA'MX system, CH-C*H*2-CH), 2.55-2.57 (1H, *m,* AA'MX system, CH-C*H*2-CH), 3.43-3.45 (2H, *m*, AMXX' systems, C*H*-CH2-C*H*), 6.54 (2H, *s*, CH-C*H*=C*H*-CH); 13C NMR (75.47 MHz, MeOD) (**5b** major product) δ 50.9 (CH2, CH-*C*H2-CH), 53.2 (CH, *C*H-CH2-*C*H), 101.0 (C, *C*Cl), 138.5 (CH, *C*H=*C*H), 187.3 (C, *C*O-CCl=*C*OH)

### bicyclo[3.2.1]oct-6-ene-2,4-dione (**6**)

3-chlorobicyclo[3.2.1]oct-6-ene-2,4-dione (**5**) (1.47 g, 8.60 mmol, 1.0 eq.) was dissolved in 35 mL of dioxane. 23 mL of acetic acid was added, followed by zinc powder (1.64 g, 25.9 mmol, 3.0 eq.). The reaction was stirred at room temperature (20 °C) for 21 h. The reaction was filtered through a pad of celite. The residue was washed with water and EtOAc. Layers were acidified with HCl (6M) to pH 2 and separated. The aqueous layer was extracted with 3x60 mL of EtOAc. Combined organic layers were washed with 2x20 mL of brine, dried over MgSO4 and concentrated to give brown oil. The crude was dry loaded to be purified by flash chromatography over silica gel (petroleum ether/AcOEt; 80/20 then 50/50) to give 729 mg of yellow oil (62% yield). Rf = 0.3-0.4 (petroleum ether/AcOEt; 80/20); <sup>1</sup>H NMR (300 MHz, CDCl3) δ 2.44-2.48 (1H, *m*, CH-C*H*2-CH), 2.52-2.60 (1H, *m*, CH-C*H*2-CH), 3.20 (1H, *d*, CO-C*H*2-CO), 3.48-3.50 (2H, *m*, C*H*-CH2-C*H*), 3.51 (1H, *d*, CO-C*H*2-CO), 6.19-6.23 (2H, *m*, C*H*=C*H*);13C NMR (75.47 MHz, CDCl3) δ 37.0 (CH2, CH-*C*H2-CH), 50.4 (CH2, CO-*C*H2- CO), 55.3 (CH, *C*H-CH2-*C*H), 134.9 (CH, *C*H=*C*H), 201.6 (C, *C*O-CH2-*C*O); IR (KBr blades) υ: 3512, 1708, 1638, 1587, 1244, 1223 cm<sup>-1</sup>; HR-MS (DCI/CH<sub>4</sub>): calculated for  $C_8H_9O_2^+$  137.0603, found 137.0607

### bicyclo[3.2.1]octane-2,4-dione (**7a**) and its enol isomer **7b**

Bicyclo[3.2.1]oct-6-ene-2,4-dione (**6**) (331 mg, 1.94 mmol, 1.0 eq.) was dissolved with 16 mL of 1,4-dioxane. The mixture was degassed with Ar for 20 min. Pd/C (10%, 104 mg, 0.10 mmol,  $0.05$  eq.) was added then the mixture was bubbled with  $H_2$  for 5 min. The reaction was stirred under H<sub>2</sub> at atmospheric pressure at room temperature (23 °C) for 1h. The reaction was filtered through a pad of celite. The residue was washed with EtOAc. The filtrate was concentrated to give a white solid of expected product (99%).

mp = 122-123°C; Rf = 0.1 (petroleum ether/EtOAc; 50/50); <sup>1</sup> H NMR (300 MHz, CDCl3) (**7a** major product) δ 1.87-1.98 (4H, *m*, CH-C*H*2-C*H*2-CH), 2.11-2.16 (2H, *m*, CH-C*H*2-CH), 3.01-3.05 (2H, *m*, C*H*-CH2-C*H*), 3.15 (1H, *dd*, CO-C*H*2-CO), 3.31 (1H, *d*, CO-C*H*2-CO); <sup>1</sup> H NMR (300 MHz, CD3OD) (**7b** major product) δ 1.58-170 (3H, *m*, CH-C*H*2-CH, CH-C*H*2- C*H*<sub>2</sub>-CH), 2.00 (1H, *d*,  $J = 11.5$  Hz, CH-C*H*<sub>2</sub>-CH), 2.06-2.18 (2H, *m*, CH-C*H*<sub>2</sub>-C*H*<sub>2</sub>-CH), 2.79-2.83 (2H, m, C*H*-CH2-C*H*), 4.90 (1H, *s*, CO-C*H*=COH); 13C NMR (75.47 MHz, CDCl3) (**7a** and **7b** mixture) δ 26.1 (CH2, A, CH-*C*H2-*C*H2-CH), 27.9 (CH2, B, CH-*C*H2-*C*H2-CH), 31.3 (CH2, A, CH-*C*H2-CH), 38.7 (CH2, B, CH-*C*H2-CH), 45.6 (CH, B, *C*H-CH2-*C*H), 49.6 (CH, A, *C*H-CH2-*C*H), 51.4 (CH2, A, CO-*C*H2-CO), 99.7 (CH, B, CO-*C*H=COH), 197.8 (C, B, *C*O-CH=*CO*), 207.2 (C, A, *CO-CH*<sub>2</sub>-*CO*); <sup>13</sup>C NMR (75.47 MHz, *CD*<sub>3</sub>*OD*) (**7b** major product) δ 28.8 (CH2, CH-*C*H2-*C*H2-CH), 39.5 (CH2, CH-*C*H2-CH), 46.9 (CH, *C*H-CH2-*C*H),

100.1 (CH, CO-*C*H=COH), 198.3 (C, *C*O-CH=*C*OH); IR (KBr pellet) υ: 1637, br. 1568 cm-1; HR-MS (DCI/CH<sub>4</sub>): calculated for  $C_8H_{11}O_2^+$  139.0759, found 139.0763

### 3-chloro-4-hydroxybicyclo[3.2.1]oct-3-en-2-one (**8**)

3-chlorobicyclo[3.2.1]oct-6-ene-2,4-dione (**7**) (50 mg, 0.3 mmol, 1.0 eq.) was dissolved in 3.5 mL of dioxane. 2.5 mL of water and acetic acid were added. The mixture was degassed with Ar for 10 min. Pd/C 10% (3.2 mg, 0.03 mmol, 0.1 eq.) was added. The mixture was degassed with H<sub>2</sub>. The reaction was heated to 55  $^{\circ}$ C under H<sub>2</sub> at atmospheric pressure for 6h. The reaction was filtered through a pad of celite. The residue was washed with EtOAc and water. The aqueous layer was separated, acidified to pH 1 with HCl (6M) and extracted with 3x15 mL of EtOAc. The combined organic layers were washed with 15 mL of brine, dried over MgSO4 and concentrated. The crude was purified by flash chromatography on silica gel (DCM, 0% to 3% of MeOH) to give 29 mg (58% yield). Rf = 0.1 (DCM/MeOH; 90/10); <sup>1</sup>H NMR (300 MHz, CDCl3) δ 1.60 (1H, *td*, CH-C*H*2-CH), 1.73-1.80 (2H, *m*, CH-C*H*2-C*H*2-CH), 2.08-2.12 (3H, *m*, CH-C*H*2-C*H*2-CH, CH-C*H*2-CH), 3.11-3.15 (2H, *m*, C*H*-CH2-C*H*); 13C NMR (75.47 MHz, CDCl3) δ 27.5 (CH2, CH-*C*H2-*C*H2-CH), 38.0 (CH2, CH-*C*H2-CH), 45.8 (CH, *C*H-CH2-*C*H), 106.1 (C, *C*Cl), 186.5 (C, *C*O-CCl=*C*OH); IR (KBr pellet) υ: 1638, 1567 cm<sup>-1</sup>; HR-MS (DCI/CH<sub>4</sub>): calculated for  $C_8H_{11}O_2Cl^+$  173.0369, found 173.0368

### 4-hydroxybicyclo[3.2.1]octan-2-one (**9**)

Rf = 0,5 (DCM/MeOH; 90/10); <sup>1</sup> H NMR (300 MHz, CDCl3) δ 1.60 (1H, *d*, CHOH-CH-C*H*2- CH2), 1.64-1.73 (1H, *m*, CO-CH-C*H*2-CH2), 1.76 (1H, *t*, CH-C*H*2-CH), 1.78-1.98 (2H, *m*, CH-C*H*2-C*H*2-CH), 2.04-2.13 (1H, *m*, CH-C*H*2-CH), 2.25 (1H, *dd*, CO-C*H*2-CHOH), 2.41- 2.46 (1H, *m*, CHOH-C*H*), 2.58 (1H, *dd*, CO-C*H*2-CHOH), 2.66 (1H, *t*, CO-C*H*), 2.81 (1H, br. *s*, CHO*H*), 4.04 (1H, *ddd*, C*H*OH); 13C NMR (75.47 MHz, CDCl3) δ 21.8 (CH2, CH-*C*H2- CH), 27.9 (CH<sub>2</sub>, CO-CH-CH<sub>2</sub>-CH<sub>2</sub>), 32.9 (CH<sub>2</sub>, CHOH-CH-CH<sub>2</sub>-CH<sub>2</sub>), 41.7 (CH, CHOH-*C*H), 44.4 (CH2, CHOH-*C*H2-CO), 49.3 (CH, CO-*C*H), 71.8 (CH, *C*HOH), 211.9 (C, *C*O); IR (KBr blades) υ: 3424 (br.), 1712, 1065 cm<sup>-1</sup>; HR-MS (DCI/CH<sub>4</sub>): calculated for  $C_8H_{12}O_2^+$ 140.0837, found 140.0834

### **General procedure for cyclic peroxide preparation**

The aldehyde (1.20 eq. )(isobutyraldehyde or aldehyde **18**) was diluted in anhydrous DCM (0.12 M). Piperidine (1.20 eq.) was added dropwise and the mixture was stirred at room temperature for 10 min. A solution of diketone (1 eq.) (**6** or **7**) and piperidine (1.10 eq.) in anhydrous DCM (0.1 M) was added dropwise to the iminium solution. The reaction was stirred at room temperature for 30 min then was concentrated. The excess of piperidine was removed under vacuum to give the Mannich base as a solid. The Mannich base was dissolved with DCM (0.1 M). The solution was stirred for 10 minutes with a saturated solution of NH4Cl in 1N HCl as a (1:1) mixture with DCM. Then the mixture was immediately extracted 3 times with EtOAc or DCM. The combined organic layers were washed with water, until pH 5-6 was reached, and brined, dried over  $MgSO_4$  and concentrated to give the autoxidation precursor (**10**, **13**, **19**, **20**). The precursor was solubilized in benzene (0.1 M) and the reaction was stirred at room temperature under  $O_2$  (1 bar). The reaction was followed by <sup>1</sup>HNMR spectroscopy analysis until consumption of the enol and enone form of the precursor. The reaction was concentrated and purified by flash chromatography over silica gel.

*Use of the Rayonnet for photoenolization:* The apparatus was equipped with 350 nm low pressure mercury lamps. Precursors (**10**, **13**, **19**, **20**) were solubilized in ethyl acetate or

benzene (0.1M). The solution was irradiated during 15 minutes then analyzed by  ${}^{1}H$  NMR. The peroxide **11** was obtained after 15 minutes of irradiation then 3h under O2 atmosphere. The peroxide **13** was obtained after 8 cycles of irradiation (15 minutes) followed by 45 minutes under  $O_2$  atmosphere.

### (+/-)-(6R,9S,9aS)-9a-hydroxy-3,3-dimethyl-3,6,7,8,9,9a-hexahydro-5H-6,9 methanocyclohepta[c][1,2]dioxin-5-one (**11**)

See : General procedure for cyclic peroxide preparation (1 day, 48% yield); White crystal; mp = decomposition; Rf = 0.45 (petroleum ether/EtOAc, 80/20); <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$ 1.37 (3H, *s*, C-C*H*3), 1.45 (3H, *s*, C-C*H*3), 1.55-1.64 (1H, *m*, C*H*2-CH2), 1.70-1.80 (3H, *m*, C*H*2-C*H*2, CH-C*H*2-CH), 1.83-1.95 (1H, *m*, C*H*2-CH2), 2.45 (1H, *d*, *J* = 12.6 Hz, CH-C*H*2- CH), 2.43-2.58 (1H, *m*, COH-C*H*), 2.82-2.86 (1H, *m*, CO-C*H*), 6.46 (1H, *s*, C=C*H*-C): 13C NMR (75.47 MHz, CDCl<sub>3</sub>) δ 23.1 (CH<sub>2</sub>, CH<sub>2</sub>-CH<sub>2</sub>), 23.5 (CH<sub>3</sub>, C-CH<sub>3</sub>), 24.5 (CH<sub>3</sub>, C-CH<sub>3</sub>), 28.6 (CH2, CH2-*C*H2), 31.8 (CH2, C-*CH2*-C), 42.0 (CH, COH-*C*H), 50.2 (CH, CO-*C*H), 78.9 (C, (CH3)2*C*-O), 100.2 (C, CH-*C*OH), 135.3 (C, *C*=CH-C), 140.1 (CH, C=*C*H-C), 201.9 (C, CH-CO-C); IR (KBr pellet) υ: 3337 (br.), 1690, 1642, 1277, 1128, 1088, 1036 cm<sup>-1</sup>; MS  $(DCI/NH<sub>3</sub><sup>+</sup>)$ : 207 (100, [MH-H<sub>2</sub>O]<sup>+</sup>), 224 (41, [M]<sup>+</sup>), 242 (34, [MNH<sub>4</sub>]<sup>+</sup>); HR-MS (DCI/CH<sub>4</sub>): calculated for  $C_{12}H_{17}O_4^{\text{+}}$  225.1127, found 225.1122

### (+/-)-3a-hydroxy-2,2-dimethylhexahydro-4,7-methanocyclohepta[b]oxireno[2,3-c]furan-8(3aH)-one (**12)**

White solid, mp= decomposition; Rf= 0.2 (petroleum ether/EtOAc, 80/20); <sup>1</sup>H NMR (300 MHz, CDCl3) δ 1.38 (3H, *s*, C-C*H*3), 1.42 (3H, *s*, C-C*H*3), 1.66-1.78 (1H, *m*, CO-CH-C*H*2- CH2), 1.82-1.88 (1H, *m*, COH-CH-C*H*2-CH2), 1.93 (1H, *td*, CH-C*H*2-CH), 2.05-2.21 (2H, *m*, CH-C*H*2-C*H*2-CH), 2.38 (1H, *d*, CH-C*H*2-CH), 2.62 (1H, *dd*, COH-C*H*-CH2), 3.00 (1H, *dd*, CO-C*H*-CH2), 3.79 (1H, s, C*H*-O-C); 13C NMR (125.77 MHz, CDCl3) δ 24.4 (CH2, CH-*C*H2- CH2-CH), 25.0 (CH3, C-*C*H3), 25.5 (CH3, C-*C*H3), 26.7 (CH2, CH-CH2-*C*H2-CH), 34.2 (CH2, CH-*C*H2-CH), 44.8 (CH, *C*H-COH), 49.9 (CH, *C*H-CO), 70.3 (C,CO-*C*-COH), 74.9 (CH, C(CH3)2-*C*H-O-C), 81.2 (C, O-*C*(CH3)2-CHO), 106.9 (C, *C*OH), 203.3 (C, *C*O); IR (KBr pellet) υ: 3433, 1722, 1295, 1126, 1116, 1089, 1062, 1023 cm<sup>-1</sup>; LR-MS (DCI/NH<sub>3</sub>): 207.0  $(100, [M-OH]^+)$ , 224.0 (30,  $[M]^+$ ), 242.0 (2%,  $[MNH_4]^+$ ); HR-MS (DCI/CH<sub>4</sub>): calculated for  $C_{12}H_{17}O_4^+$  225.1127, found 225.1132

(+/-)-(6S,9R,9aS)-9a-hydroxy-3,3-dimethyl-3,6,9,9a-tetrahydro-5H-6,9 methanocyclohepta[c][1,2]dioxin-5-one (**14**)

See : General procedure for cyclic peroxide preparation (36 days, 49% yield); White crystal; mp=decomposition;  $Rf = 0.2$  (petroleum ether/EtOAc, 80/20); <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$ 1.29 (3H, *s*, C-C*H*3), 1.35 (3H, *s*, C-C*H*3), 2.40 (1H, *dt*, *J* = 12 Hz, *J* = 5 Hz, CH-C*H*2-CH), 2.66 (1H, *d*, *J* = 12 Hz, CH-C*H*2-CH), 3.01 (1H, *dd*, *J* = 5 Hz, *J* = 3 Hz, COH-C*H*), 3.21 (1H, *dd*, *J* = 5 Hz, *J* = 3 Hz, CO-C*H*), 6.10 (1H, *dd*, *J* = 5.7 Hz, *J* = 3 Hz, CH-C*H*=C*H*-CH) 6.16 (1H, *dd*,  $J = 5.7$  Hz,  $J = 3$  Hz, CH-C*H*=C*H*-CH), 6.43 (1H, *s*, C=C*H*-C); <sup>13</sup>C NMR (75.47) MHz, CDCl3) δ 23.6 (CH3, C-*C*H3), 24.2 (CH3, C-*C*H3), 37.7 (CH2, CH-*CH2*-CH), 46.6 (CH, COH-*C*H), 55.0 (CH, CO-*C*H), 79.5 (C, (CH3)2*C*-O), 98.9 (C, CH-*C*OH), 135.5 (CH, CH-*C*H=CH-CH), 136.2 (CH, CH-CH=*C*H-CH), 136.3 (C, *C*=CH-C), 140.5 (CH, C=*C*H-C), 197.1 (C, CH-*C*O-C); IR (KBr pellet) υ: 3363 (br.), 1694, 1639, 1263, 1110, 1085, 1052 cm-1; HR-MS (DCI/CH<sub>4</sub>): calculated for  $C_{12}H_{15}O_4^+$  223.0970, found 223.0979

### **General procedure for methylation**

To a solution of the peroxy-alcohol (1.0 eq.) in anhydrous THF (0.025 M) at -78°C, Buli (1.6 M, 1.0 eq.) was added dropwise under Ar. After 10 min, methyl-triflate (1.2 eq.) was added dropwise. The reaction was quenched with an aqueous saturated solution of NH4Cl. The reaction was diluted with water and phases were separated. The aqueous layer was extracted with EtOAc. The combined organic layers were washed with brine, dried over  $MgSO<sub>4</sub>$  and concentrated. The crude was purified by flash chromatography over silica gel.

(+/-)-(6R,9S,9aS)-9a-methoxy-3,3-dimethyl-3,6,7,8,9,9a-hexahydro-5H-6,9 methanocyclohepta[c][1,2]dioxin-5-one (**15**)

 $(-70^{\circ}C, 4h, 48\%$  yield); Colorless oil; Rf = 0.45 (petroleum ether/EtOAc, 85/15); <sup>1</sup>H NMR  $(300 \text{ MHz}, \text{CDCl}_3)$   $\delta$  1.29 (3H, *s*, C-CH<sub>3</sub>), 1.43 (3H, *s*, C-CH<sub>3</sub>), 1.58-1.73 (3H, *m*, CH<sub>2</sub>-CH<sub>2</sub>, CH-C*H*2-CH), 1.78-1.95 (2H, *m*, C*H*2-C*H*2), 2.29 (1H, *d*, CH-C*H*2-CH), 2.70 (1H, *t*, COH-C*H*), 2.85 (1H, *t*, CO-C*H*), 3.38 (3H, *s*, OC*H*3), 6.51 (1H, *s*, C=C*H*-C); 13C NMR (75.47 MHz, CDCl<sub>3</sub>) δ 23.4 (CH<sub>3</sub>, C-*C*H<sub>3</sub>), 23.5 (CH<sub>2</sub>, C-*C*H<sub>2</sub>-C), 24.8 (CH<sub>3</sub>, C-*C*H<sub>3</sub>), 29.1 (CH<sub>2</sub>, *C*H2-*C*H2), 31.4 (CH2, *C*H2-*C*H2), 38.7 (CH, COCH3-*C*H), 50.3 (CH, CO-*C*H), 50.4 (CH3, O*C*H3), 78.2 (C, (CH3)2*C*-O), 102.9 (C, CH-*C*OH), 133.5 (C, *C*=CH-C), 140.6 (CH, C=*C*H-C), 201.6 (C, CH-CO-C); IR (KBr blades) υ: 1701, 1649, 1270, 1126, 1091, 1074, 1003 cm<sup>-1</sup>; HR-MS (DCI/CH<sub>4</sub>): calculated for  $C_{13}H_{19}O_4^+$  239.1283, found 239.1287

(+/-)-(6S,9R,9aS)-9a-methoxy-3,3-dimethyl-3,6,9,9a-tetrahydro-5H-6,9 methanocyclohepta[c][1,2]dioxin-5-one (**16**)

(-70°C, 2.5h, 50% yield); Colorless oil;  $Rf = 0.4$  (petroleum ether/EtOAc, 90/10); <sup>1</sup>H NMR (300 MHz, CDCl3) δ 1.26 (3H, *s*, C-C*H*3), 1.32 (3H, *s*, C-C*H*3), 2.30-2.37 (1H, *m*, AA'MX system, CH-CH<sub>2</sub>-CH), 2.49 (1H, *d*, CH-CH<sub>2</sub>-CH), 3.15-3.20 (2H, *m*, 2xCH-CH<sub>2</sub>-CH), 3.42 (3H, *s*, O-C*H*3), 6.07-6,12 (2H, *m*, ABX systems, CH-C*H*=C*H*-CH), 6.43 (1H, *s*, C=C*H*-C); <sup>13</sup>C NMR (75.47 MHz, CDCl<sub>3</sub>) δ 23.4 (CH<sub>3</sub>, C-CH<sub>3</sub>), 24.6 (CH<sub>3</sub>, C-CH<sub>3</sub>), 37.1 (CH<sub>2</sub>, CH-*CH2*-CH), 43.4 (CH, COH-*C*H), 50.5 (CH3, O*C*H3), 55.0 (CH, CO-*C*H), 78.9 (C, (CH3)2*C*-O), 101.5 (C, CH-*C*OH), 133.9 (C, *C*=CH-C), 135.8 (CH, CH-*C*H=CH-CH), 136.2 (CH, CH-CH=*C*H-CH), 141.1 (CH, C=*C*H-C), 197.0 (C, CH-*C*O-C); IR (KBr blades) υ: 1704, 1648, 1258, 1106, 1085, 1057 cm<sup>-1</sup>; HRMS (DCI/ CH<sub>4</sub>): calculated for C<sub>13</sub>H<sub>17</sub>O<sub>4</sub><sup>+</sup> 237.1127, found 237.1126

### 1-(7-chloroquinolin-4-yl)piperidine-4-carbaldehyde (**18**)

Alcohol **17** (200 mg, 0.72 mmol, 1.0 eq.) and IBX (407 mg, 1.45 mmol, 2.0 eq.) in 5 mL of acetone were heated at 60°C for 5h. Then the reaction was filtered. The white precipitate was washed with DCM. The filtrate was concentrated to give 237 mg (99% yield) of a yellow oil of aldehyde. Rf = 0.44 (DCM/EtOAc, 50/50); <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  1.90-2.03 (2H, *m*, CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>), 2.10-2.19 (2H, *m*, CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>), 2.48-2.52 (1H, *m*, CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>), 2.91-2.99 (2H, *m*, CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>), 3.50 (2H, *td*, CH<sub>2</sub>-CH<sub>2</sub>-CH-CH2-C*H*2), 6.81 (1H, *d*, N=CH-C*H*), 7.41 (1H, *dd*, CCl=C*H*-CH), 7.87 (1H, CCl=CH-C*H*), 8.02 (1H, *d*, C*H*-CCl), 8.68 (1H, *d*, N=C*H*-CH), 9.76 (1H, *d*, C*H*O); 13C NMR (75.47 MHz, CDCl<sub>3</sub>) δ 25.4 (CH<sub>2</sub>, CH<sub>2</sub>-CH<sub>2</sub>-CH-CH<sub>2</sub>-CH<sub>2</sub>), 25.5 (CH<sub>2</sub>, CH<sub>2</sub>-CH<sub>2</sub>-CH-*C*H<sub>2</sub>-CH<sub>2</sub>), 47.6 (CH, CH2-CH2-*C*H-CH2-CH2), 51.7 (CH2, *C*H2-CH2-CH-CH2-*C*H2), 109.1 (CH, N=CH-*C*H=C), 122.0 (C, C-*C*=CH), 125.0 (CH, CCl=*C*H-CH), 126.3 (CH, CCl=CH-*C*H), 128.7

(CH, CCl-*C*H=C), 134.9 (C, *C*Cl), 150.0 (C, CCl-CH=*C*), 151.8 (CH, N=*C*H-CH-C), 157.3 (C, N=CH-CH-*C*), 202.9 (CH, *C*HO); IR (ATR) υ: 3062, 2945, 2920, 2816, 1724, 1607, 1574, 1425 and 869 cm<sup>-1</sup>; LR-MS (DCI/NH<sub>3</sub>): 275 (100, [MH]<sup>+</sup>), 277 (34%, [MH+2]<sup>+</sup>); HR-MS (ESI): calculated for  $C_{15}H_{16}N_2OCl^+$ , 275.0951, found 275.0953

(+/-)-1-(7-chloroquinolin-4-yl)-9a'-hydroxy-9',9a'-dihydrospiro[piperidine-4,3'- [6,9]methanocyclohepta[c][1,2]dioxin]-5'(6'H)-one (**21**)

See : General procedure for cyclic peroxide preparation (DCM, 33 days, 19% yield); Colorless oil;  $\overline{Rf} = 0.11$  (DCM/EtOAc, 80/20); <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  1.84-2.00 (2H, *m*, C-C*H*<sub>2</sub>-CH<sub>2</sub>-N), 2.11-2.21 (2H, *m*, C-C*H*<sub>2</sub>-CH<sub>2</sub>-N), 2.42-2.49 (1H, *m*, CH-C*H*<sub>2</sub>-CH), 2.71 (1H, *d*, CH-CH<sub>2</sub>-CH), 3.04-3.07 (1H, *m*, CH-CH<sub>2</sub>-CH), 3.13 (1H, *dt*, C-CH<sub>2</sub>-CH<sub>2</sub>-N), 3.23-3.28 (2H, *m*, CH-CH2-C*H*, C-CH2-C*H*2-N), 3.30-3.38 (2H, *m*, C-CH2-C*H*2-N), 6.12-6.19 (2H, *m*, C*H*=C*H*), 6.48 (1H, *s*, C=C*H*-CO), 6.85 (1H, *d*, N-CH=C*H*-C), 7.42 (1H, *dd*, C-CH=C*H*-CCl), 7.86 (1H, *d*, C-C*H*=CH-CCl), 8.06 (1H, *d*, C-C*H*=CCl), 8.71 (1H, *d*, N-C*H*=CH-C); 13C NMR (75.47 MHz, CDCl3) δ 31.4 (CH2, C(*C*H2)2), 33.1 (CH2, C(*C*H2)2), 37.8 (CH2, CH-*C*H2- CH), 46.8 (CH, *C*H-CH2-CH), 47.5 (CH2, N(*C*H2)2), 48.0 (CH2, N(*C*H2)2), 55.1 (CH, CH-CH2-*C*H), 78.4 (C, CH-*C*-(CH2)2), 99.4 (C, *C*OH), 109.3 (CH, C=*C*H-CH=N), 122.0 (C, CH=C-*C*-CH), 125.0 (CH, C-*C*H=CH-CCl), 126.5 (CH, C-CH=*C*H-CCl), 128.9 (CH, C-*C*H=CCl), 135.2 (C, *C*Cl), 135.5 (CH, *C*H=CH), 136.2 (CH, CH=*C*H), 138.0 (C, COH-*C*=CH), 138.4 (CH, COH-C=*C*H), 150.0 (C, N-*C*-CH), 151.9 (CH, C=CH-*C*H=N), 157.3 (C, CH=*C*-C-CH), 196.6 (C, *C*O); IR (ATR) υ: 3060, 1700, 1572 cm-1; MS (CI/NH3) : 424 (5, [MH]<sup>+</sup>), 382 (5), 260 (100), 217 (21), 190 (23), 155 (30%); HR-MS (DCI/CH<sub>4</sub>): calculated for  $C_{23}H_{22}N_2O_4Cl^2$ , 425.1268, found 425.1253

(+/-)-1-(7-chloroquinolin-4-yl)-9a'-hydroxy-7',8',9',9a'-tetrahydrospiro[piperidine-4,3'- [6,9]methanocyclohepta[c][1,2]dioxin]-5'(6'H)-one (**22**)

See : General procedure for cyclic peroxide preparation (DCM, 15 days, 34% yield); White solid; mp = 138°C followed by decomposition at 140°C;  $Rf = 0.28$  (DCM/MeOH, 97/3); <sup>1</sup>H NMR (300 MHz, CDCl3) δ 1.62-1.71 (1H, *m*, CH-C*H*2-CH2-CH), 1.74-1.88 (3H, *m*, CH-C*H*2- CH, CH-C*H*2-CH2-CH), 1.89-2.29 (5H, *m*,C-C*H*2-CH2-N, CH-C*H*2-CH2-CH), 2.54 (1H, *d*, C*H*-CH2-CH), 2.61-2.65 (1H, *m*, C*H*-CH2-CH), 2.90-2.94 (1H, *m*, CH-CH2-C*H*), 3.27-3.43 (3H, *m*, C-CH2-C*H*2-N), 6.52 (1H, *s*, C=C*H*-CO), 6.85 (1H, *d*, N-CH=C*H*-C), 7.41 (1H, *dd*, C-CH=C*H*-CCl), 7.86 (1H, *d*, C-C*H*=CH-CCl), 8.07 (1H, *s*, C-C*H*=CCl), 8.70 (1H, br. *s*, N-C*H*=CH-C); 13C NMR (75.47 MHz, CDCl3) δ 23.3 (CH2, *C*H2-CH2), 28.6 (CH2, CH-*C*H2), 31.7 (CH2, C(*C*H2)2), 32.0 (CH2, CH-*C*H2-CH), 33.0 (CH2, C(*C*H2)2), 42.3 (CH, *C*H-CH2- CH), 47.6 (CH2, N(*C*H2)2), 48.0 (CH2, N(*C*H2)2), 50.3 (CH, CH-CH2-*C*H), 77.7 (C, CH-*C*- (CH2)2), 100.8 (C, *C*OH), 109.3 (CH, C=*C*H-CH=N), 122.0 (C, CH=C-*C*-CH), 125.0 (CH, C-*C*H=CH-CCl), 126.5 (CH, C-CH=*C*H-CCl), 128.7 (CH, C-*C*H=CCl), 135.3 (C, *C*Cl), 137.2 (C, COH-*C*=CH), 137.9 (CH, COH-C=*C*H), 149.8 (C, N-*C*-CH), 151.8 (CH, C=CH-*C*H=N), 157.4 (C, CH=*C*-C-CH), 201.4 (C, *C*O); IR (ATR) υ: br. 3360, 1697, 1574, 1200, 1102, 1088 cm<sup>-1</sup>; MS (CI/NH<sub>3</sub>): 427 (5, [MH]<sup>+</sup>), 429 (1, [MH+2]<sup>+</sup>), 261 (100, C<sub>14</sub>H<sub>14</sub>ClN<sub>2</sub>O<sup>+</sup>), 263  $(32\%, [C_{14}H_{14}CIN_2O+2]^+);$  HR-MS (DCI/CH<sub>4</sub>): calculated for  $C_{23}H_{24}N_2O_4Cl^+$  427.1425, found 427.1416

(+/-)-1-(7-chloroquinolin-4-yl)-9a'-methoxy-9',9a'-dihydrospiro[piperidine-4,3'- [6,9]methanocyclohepta[c][1,2]dioxin]-5'(6'H)-one (**23**)

See : General procedure for methylation (-70°C to -65°C, 2.5h, 16%); <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 1.92-1.99 (2H, *m*, C-(CH<sub>2</sub>-CH<sub>2</sub>)<sub>2</sub>-N), 2.07-2.21 (2H, *m*, C-CH<sub>2</sub>-CH<sub>2</sub>-N), 2.35-2.43  $(1H, m, CH-CH_2-CH), 2.54 (1H, d, CH-CH_2-CH), 3.10-3.18 (1H, m, C-(CH_2-CH_2)-N), 3.19-$ 3.28 (3H, *m*, CH-CH<sub>2</sub>-CH, C-(CH<sub>2</sub>-CH<sub>2</sub>)<sub>2</sub>-N), 3.31-3.38 (2H, *m*, C-(CH<sub>2</sub>-CH<sub>2</sub>)<sub>2</sub>-N), 3.48 (3H, *s*, OCH3), 6.11-6.13 (2H, *m*, C*H*=C*H*), 6.48 (1H, *s*, C=C*H*-CO), 6.86 (1H, *d*, N-CH=C*H*-C), 7.43 (1H, *dd*, J = 2.1 Hz, C-CH=C*H*-CCl), 7.88 (1H, *d*, C-C*H*=CH-CCl), 8.05 (1H, *d*, C-C*H*=CCl), 8.71 (1H, *d*, N-C*H*=CH-C); 13C NMR (75.47 MHz, CDCl3) δ 31.7 (CH2, C(*C*H2)2), 32.9 (CH2, C(*C*H2)2), 37.2 (CH2, CH-*C*H2-CH), 43.3 (CH, *C*H-CH2-CH), 47.7 (CH2, N(*C*H2)2), 48.1 (CH2, N(*C*H2)2), 50.5 (CH3, O*C*H3), 55.1 (CH, CH-CH2-*C*H), 77.7 (C, CH-*C*- (CH2)2), 102.0 (C, *C*OMe), 109.3 (CH, C=*C*H-CH=N), 122.0 (C, CH=C-*C*-CH), 125.0 (CH, C-*C*H=CH-CCl), 126.5 (CH, C-CH=*C*H-CCl), 128.9 (CH, C-*C*H=CCl), 135.2 (C, *C*Cl), 135.8 (C, COH-*C*=CH), 136.1 (CH, *C*H=CH), 136.2 (CH, CH=*C*H), 139.0 (CH, COH-C=*C*H), 150.0 (C, N-*C*-CH), 151.9 (CH, C=CH-*C*H=N), 157.4 (C, CH=*C*-C-CH), 196.7 (C, *C*O); IR (ATR) υ: 3064, 1703, 1574 cm<sup>-1</sup>; LR-MS (CI/NH<sub>3</sub>) : 438 (42, [MH]+), 372 (46), 260 (100), 217 (52), 191 (66), 155 (66%); HR-MS (DCI/CH<sub>4</sub>): calculated for  $C_{24}H_{24}N_2O_4Cl^+$ , 439.1425, found 439.1419

### **Acknowledgments**

1

We acknowledge the "Ministère de l'Education Nationale" for a grant to J. Ruiz.

4 D. J. Creek, W. N. Charman, F. C. K. Chiu, R. J. Prankerd, Y. Dong, J. L. Vennerstrom, S. A. Charman, *Antimicrob. Agents Chemother.*, 2008, **52**, 1291-1296.

7 E. L. Ghisalberti, *Phytochemistry* 1996, **41,** 7-22.

<sup>1</sup> A. Robert, B. Meunier, *J. Am. Chem. Soc.*, 1997, **119**, 5968-5969.

<sup>2</sup> A. Robert, B. Meunier, *Chem. Eur. J.*, 1998, **4**, 1287-1296.

<sup>3</sup> A. Robert, O. Dechy-Cabaret, J. Cazelles, B. Meunier; *Acc. Chem. Res.*, 2002, **35**, 167-174.

<sup>5</sup> P. M. O'Neill, R. K. Amewu, G. L. Nixon, F. Bousejra ElGarah, M. Mungthin, J. Chadwick,

A. E. Shone, L. Davies, B. K. Park, S. Wittlin, R. Brun, M. Preschel, K. Zhang, S. A. Ward, *Angew. Chem. Int. Ed.*, 2010, **49**, 5693-5697.

<sup>6</sup> P. O'Neill, L. P. D. Bishop, N. L. Searle, J. L. Maggs, R. C. Storr, S. A. Ward, P. G. Bray, R. C. Storr B. K. Park, *Tet. Lett.*, 1997, **38**, 4263-4266.

<sup>8</sup> F. Najjar, L. Gorrichon, M. Baltas, H. Vial, T. Tzedakis, C. André-Barrès, *Bioorg. Med. Chem. Lett.*, 2004, **14***,* 1433-1436.

<sup>9</sup> F. Najjar, L. Gorrichon, M. Baltas, C. André-Barrès, H. Vial; *Org. Biomol. Chem*., 2005, **3**, 1612-1614.

<sup>10</sup> C. André-Barrès, F. Najjar, A.-L. Bottalla, S. Massou, C. Zedde, M. Baltas, L. Gorrichon, *J. Org. Chem.,* 2005, **70**, 6921-6924.

<sup>11</sup> F. Najjar, M. Baltas, L. Gorrichon, Y. Moreno, T. Tzedakis, H. Vial, C. André-Barrès, *Eur*. *J. Org. Chem.*, 2003, 3335-3343.

12 R. Beaudegnies, C. Lüthy, A. Edmunds, J. Schaetzer, S. Wenderborn; *World Intellectual Property Organisation*, 2005, WO 2005/123667 A1

13 D. C. Law, S. W. Tobey; *J. Am. Chem. Soc.*, 1968, **90**, 2376-2386

14 G. M. Sheldrick, Acta Crystallogr., 2008, A**64**, 112-122.

<sup>15</sup> **Crystal data for 11**: C<sub>12</sub>H<sub>16</sub>O<sub>4</sub>, M= 224.25, triclinic,  $a = 6.4719(5)$ ,  $b = 8.7411(6)$ ,  $c =$ 10.9321(8) Å,  $V = 559.87(7)$  Å<sup>3</sup>,  $T = 193$  K, space group *P-1*,  $Z = 2$ , 10737 reflections collected, 2765 unique ( $R_{\text{int}} = 0.0203$ ),  $R_1[I > 2\sigma(I)] = 0.0379$ . The final  $wR(F2)$  was 0.1055 (all data). Crystallographic data have been deposited at the Cambridge Crystallographic Data Centre and have been assigned the deposition number CCDC 997078.

<sup>16</sup> Crystal data for 14: C<sub>12</sub>H<sub>14</sub>O<sub>4</sub>, M= 222.23, monoclinic,  $a = 6.5048(5)$ ,  $b = 20.2812(16)$ , *c*  $= 8.3695(6)$  Å,  $V = 1088.27(14)$  Å<sup>3</sup>,  $T = 193$  K, space group  $P2_1/c$ ,  $Z = 4$ , 17567 reflections collected, 2338 unique ( $R_{\text{int}} = 0.0371$ ),  $R_1[I > 2\sigma(I)] = 0.0372$ . The final  $wR(F2)$  was 0.0908 (all data). Crystallographic data have been deposited at the Cambridge Crystallographic Data Centre and have been assigned the deposition number CCDC 997079.

 $17$  M. J. Frisch, G. W. Trucks, H. B. Schlegel, G. E. Scuseria, M. A. Robb, J. R. Cheeseman, G. Scalmani, V. Barone, B. Mennucci, G. A. Petersson, H. Nakatsuji, M. Caricato, X. Li, H. P. Hratchian, A. F. Izmaylov, J. Bloino, G. Zheng, J. L. Sonnenberg, M. Hada, M. Ehara, K. Toyota, R. Fukuda, J. Hasegawa, M. Ishida, T. Nakajima, Y. Honda, O. Kitao, H. Nakai, T. Vreven, J. A. Montgomery, Jr., J. E. Peralta, F. Ogliaro, M. Bearpark, J. J. Heyd, E. Brothers, K. N. Kudin, V. N. Staroverov, R. Kobayashi, J. Normand, K. Raghavachari, A. Rendell, J. C. Burant, S. S. Iyengar, J. Tomasi, M. Cossi, N. Rega, J. M. Millam, M. Klene, J. E. Knox, J. B. Cross, V. Bakken, C. Adamo, J. Jaramillo, R. Gomperts, R. E. Stratmann, O. Yazyev, A. J. Austin, R. Cammi, C. Pomelli, J. W. Ochterski, R. L. Martin, K. Morokuma, V. G. Zakrzewski, G. A. Voth, P. Salvador, J. J. Dannenberg, S. Dapprich, A. D. Daniels, Ö. Farkas, J. B. Foresman, J. V. Ortiz, J. Cioslowski, and D. J. Fox, Gaussian 09, Revision **A.1**, Gaussian, Inc., Wallingford CT, 2009.

18A.D. Becke, *J. Chem. Phys.* 1993, **98**, 5648. - C. Lee, W. Yang, R.G. Parr, *Phys. Rev. B*, 1988, **37**, 785.

19 V. Bernat, M. Coste, C. André-Barrès; *New J. Chem.*, 2009, **33**, 2380-2384.

 $\overline{^{20}}$  J. Ruiz, PhD Thesis, University of Toulouse, 2013, France.

21 R. E. Desjardins, C. J. Canfield, J. D. Haynes, J. D. Chulay, *Antimicob. Agents Chemother.*, 1979, **16**, 710-718.